Yarger Wealth Strategies LLC Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Yarger Wealth Strategies LLC lessened its position in Johnson & Johnson (NYSE:JNJ) by 54.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,469 shares of the company’s stock after selling 1,746 shares during the quarter. Yarger Wealth Strategies LLC’s holdings in Johnson & Johnson were worth $212,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Total Wealth Planning LLC boosted its holdings in Johnson & Johnson by 4.6% during the 4th quarter. Total Wealth Planning LLC now owns 2,004 shares of the company’s stock valued at $290,000 after acquiring an additional 89 shares during the period. Hennessy Advisors Inc. boosted its stake in shares of Johnson & Johnson by 2.7% during the fourth quarter. Hennessy Advisors Inc. now owns 55,350 shares of the company’s stock valued at $8,005,000 after purchasing an additional 1,450 shares during the period. Capital Planning LLC grew its holdings in shares of Johnson & Johnson by 13.6% in the fourth quarter. Capital Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after purchasing an additional 183 shares during the last quarter. KMG Fiduciary Partners LLC lifted its holdings in Johnson & Johnson by 5.7% during the 4th quarter. KMG Fiduciary Partners LLC now owns 37,750 shares of the company’s stock valued at $5,459,000 after buying an additional 2,025 shares in the last quarter. Finally, Decker Retirement Planning Inc. purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $149,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Guggenheim lifted their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Royal Bank of Canada increased their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Morgan Stanley lifted their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $174.29.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Down 0.5 %

NYSE:JNJ opened at $147.03 on Friday. The firm has a 50 day moving average of $148.51 and a 200 day moving average of $155.96. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The stock has a market capitalization of $353.99 billion, a price-to-earnings ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.37%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.